These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 22, 2013.
Represents actual sale price.
Includes an aggregate of 12,655 shares of common stock issuable pursuant to previously reported restricted stock unit awards that have not vested.
The option became exercisable as to 25% of the shares on December 2, 2005, and becomes exercisable as to 1/48th of the shares each full month thereafter.
The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here. Genomic Health next reports earnings on April 28, 2014.
To receive a free e-mail notification whenever Genomic Health makes a similar move, sign up!
Other recent filings from the company include the following:
Genomic Health's President and CEO just cashed-in 4,300 options - Nov. 14, 2014
Genomic Health's COO just cashed-in 4,000 options - Nov. 12, 2014
Genomic: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers - Nov. 10, 2014
Genomic Health director just cashed-in 3,000 options - Nov. 5, 2014
Genomic Health Announces Third Quarter 2014 Financial Results And Reports Continued Growth In U.S. Invasive Breast Cancer Business - Nov. 4, 2014